Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BELLUS Health Inc BLUSD


Primary Symbol: T.BLU

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.


TSX:BLU - Post by User

Post by Stocktreeon Apr 20, 2023 10:59am
247 Views
Post# 35405225

The wonderful Bellus story: not ours.

The wonderful Bellus story: not ours.2 very different stories. those of Bellus' chronic cough medicine and Spectral Medical's septic shock treatment.

BLU-5937 phase 3 trial

Randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study
First patient expected to be enrolled in the fourth quarter of 2022;
Topline results from CALM-1 expected in 2H 2024
And that's for 675 patients (no problem finding patients)
160 sites
For a drug that would be very widely used to treat a chronic condition suffered by millions.
The company was bought out a few months after the start of the phase 3 trial (interest was there).


Tigris phase 3 trial
No end in site (started in 2019)
50 patients randomized over 150 during that time.
Open-label study designed to find a sub-sub-sub group of septic patients that might statistically benefit from PMX.
The medical community and patients seem very reluctant to use this treatment.
(cannot find participants in the US, PMX is approved in Canada and not used...)
Not a stand-alone treatment (to be administered in addition to SoC), which means very expensive and highly likely insurance companies would not be inclined to reimburse.
Who knows what will be considered a success leading to an FDA approval?
Company always fails to meet targets.
Company nerver seizes the chance of selling its product.
Company wastes money.
Company gives out its assets.
Shady management behaviors (conference calls, communiques, share handouts)
We can stop using the "millions of people worldwide", as we do not have PMX rights for outside NA.

<< Previous
Bullboard Posts
Next >>